TISI Stock Recent News

WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, aims to set new efficiency standards in the industry, to prove that innovation and cost-effectiveness can coexist. Built with the rising cost of drug development in mind, Tevogen's model aligns with current drug price reform efforts while challenging traditional biotech financing norms to ensure long-term sustainability.

Napoleonville, Louisiana--(Newsfile Corp. - February 21, 2025) - Impact Fusion (OTC Pink: IFUS) announced today that AgriGlow BioTech has arranged for IFUS executives, Marc Walther (IFUS CEO) and Trey Schmidt (VP of International Affairs), to join the AgriGlow BioTech team to meet with Mr. Meenesh Shah, Chairman of the National Dairy Development Board (NDDB), as well as Mr.

HAUPPAUGE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced today that Thomas X.

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced changes to its executive leadership team, aligned with the Company's external reporting structure. After 21 years of dedicated service to IFF, Simon Herriott, president of Health and Biosciences, will step down. Effective March 1, Leticia Gonçalves, ADM's president of precision fermentation and ADM Ventures, will join IFF as president of Health and Biosciences. “Since 2019, Simon has driven growth and operational effectiveness through innovat.

MIDLAND, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback” or the “Company”) today announced its leadership transition plan, representing the culmination of a thorough succession planning process that will position the Company for continued long term outperformance. Travis D. Stice, who has led Diamondback as Chief Executive Officer since January 2012 and joined the Board of Directors in November 2012 following the Company's initial public offering, intends to step down as Chief Executive Officer effective as of the Company's 2025 Annual Meeting of Stockholders. At that time, Mr. Stice will transition from Chief Executive Officer to Executive Chairman of the Board, and Kaes Van't Hof, current President of the Company, will succeed Mr. Stice as Chief Executive Officer and will join the Board of Directors. Effective today, Jere Thompson, current Executive Vice President of Strategy and Corporate Development, will assume the role of

MIDLAND, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper” or the “Company”) today announced its leadership transition plan, representing the culmination of a thorough succession planning process and ensuring a seamless leadership transition that will position the Company for continued long term outperformance. Travis D. Stice will transition from his role as Chief Executive Officer, effective immediately. Kaes Van't Hof, current President of the Company, will succeed Mr. Stice as Chief Executive Officer. Austen Gilfillian, current Vice President of Viper, will assume the role of President, also effective immediately.

Childs, Cooper, Thompson Bring Decades of Expertise to Heliospace BERKELEY, CALIFORNIA / ACCESS Newswire / February 20, 2025 / Heliospace Corp., a subsidiary of Helio Corporation (OTC PINK:HLEO), has announced that it has tapped three former JPL and NASA senior technical staff members for its Space Systems Engineering Team. Brian Childs, James Cooper, and Shaun Thomson are the latest additions to the Heliospace experienced technical roster.

TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- G2 Goldfields Inc. (“G2” or the “Company”) (TSX: GTWO; OTCQX: GUYGF) is pleased to announce the appointment of Ms. Jacqueline Wagenaar as VP, Investor Relations and the promotion of Mr.

- Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn. , Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor.

WELLSTAR has made two key additions to its management team, Sarah Xu has joined as Vice President of Growth Operations and Frank Seiferth has joined as Vice President of Product. Sarah and Frank bring deep industry experience and leadership backgrounds including Google, Ambience Healthcare, Blue-Dot and Amdocs.